Y Intercept Hong Kong Ltd Sells 6,887 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Y Intercept Hong Kong Ltd lowered its position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 31.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,997 shares of the medical device company's stock after selling 6,887 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in AtriCure were worth $458,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in ATRC. Arcadia Investment Management Corp MI acquired a new position in AtriCure in the 3rd quarter valued at approximately $28,000. Heck Capital Advisors LLC acquired a new stake in AtriCure in the fourth quarter valued at $60,000. Venturi Wealth Management LLC increased its holdings in AtriCure by 1,337.6% in the fourth quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock valued at $69,000 after purchasing an additional 2,100 shares during the period. KBC Group NV raised its position in AtriCure by 65.3% during the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock worth $72,000 after purchasing an additional 932 shares during the last quarter. Finally, R Squared Ltd acquired a new position in AtriCure during the 4th quarter worth about $89,000. Institutional investors own 99.11% of the company's stock.

AtriCure Stock Down 2.6 %

ATRC stock traded down $1.00 during midday trading on Thursday, reaching $36.85. 149,864 shares of the company's stock traded hands, compared to its average volume of 580,624. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. The firm's fifty day moving average price is $37.66 and its 200-day moving average price is $32.98. AtriCure, Inc. has a 52 week low of $18.94 and a 52 week high of $43.11. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -38.79 and a beta of 1.46.

Remove Ads

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Stifel Nicolaus increased their target price on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. JMP Securities restated a "market outperform" rating and set a $60.00 target price on shares of AtriCure in a research report on Monday, February 10th. Piper Sandler lifted their target price on AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. JPMorgan Chase & Co. boosted their price target on AtriCure from $40.00 to $51.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Finally, Canaccord Genuity Group lifted their price objective on shares of AtriCure from $61.00 to $66.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $51.56.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.